Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy	B-cell chronic lymphocytic leukemia, Blood Protein Disorders, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Waldenstrom macroglobulinemia, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, skin disorder, skin neoplasm, skin squamous cell carcinoma, vascular disorder, vascular hemostatic disease	Recruiting	Phase 4	2026-08-11		NCT07426484

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Checkpoint Therapeutics, Inc.	2
Dana-Farber Cancer Institute	324

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Brigham and Women's Hospital	Boston	United States	511
Dana-Farber Cancer Institute	Boston	United States	68